Merck (MRK) EBITDA (2009 - 2026)

Merck (MRK) has reported EBITDA for 18 consecutive years, with -$584.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 111.7% year-over-year to -$584.0 million in Q2 2026; TTM through Jun 2026 was $10.1 billion, a 47.0% decrease from a year earlier, with the FY2025 full-year figure at $21.2 billion, up 6.56% from the prior year.
• EBITDA was -$584.0 million for Q2 2026 at Merck, up from -$3.4 billion in the prior quarter.
• Over five years, EBITDA peaked at $7.6 billion in Q4 2025 and troughed at -$5.2 billion in Q2 2023.
• A 5-year average of $3.6 billion and a median of $4.6 billion in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 204.83% in 2023 and jumped 217.14% in 2024, its largest moves.
• Over 5 years, EBITDA stood at $3.4 billion in 2022, then tumbled by 37.2% to $2.2 billion in 2023, then jumped by 99.03% to $4.3 billion in 2024, then jumped by 76.59% to $7.6 billion in 2025, then tumbled by 107.7% to -$584.0 million in 2026.
• The last three EBITDA figures came in at -$584.0 million (Q2 2026), -$3.4 billion (Q1 2026), and $7.6 billion (Q4 2025), per Business Quant data.